NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Capricor Therapeutics, Inc. CAPR
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-2.26
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-46.6%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 19-year series below
Revenue
Net income
Per share
USD -2.26
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-46.6%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-39.9%
Each USD of equity lost 47 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+178.8%
Change, 10 years—
The share count grew 179% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 355.9M
total assets, end of FY2025
Total assetsUSD 355.9M
EquityUSD 305.8M
CashUSD 287.8M
Current ratio9.01×
Equity funds 86% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
Operating income $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
Income tax $B
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
0.0
·
·
·
·
·
Net income $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.26
−1.15
−0.83
−1.18
−0.87
−0.88
−2.06
−5.17
0.09
−1.01
−0.81
−0.53
−0.85
−0.21
−0.13
−0.19
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−46.6
−48.2
−129.6
−134.5
−67.2
−78.0
−133.4
−191.8
67.3
·
·
·
−407.9
−63.2
−66.7
−78.2
−25.6
−113.1
−113.4
Shares out B
0.06
0.05
0.03
0.03
0.02
0.02
0.01
0.00
0.03
0.02
0.02
0.01
0.01
0.01
0.04
0.03
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
47 of 47
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed